The tumors from patients 4,010,016 and 4,010,017 each had 14 such genes with significant promoter hypomethylation in response to FdCyd-THU treatment, including several genes with known tumor suppressor function: BMPR1B [30], CDH1 [31], FCGRT [32], LRIG3 [33], and MAMDC2 [34] for patient 4,010,016, and RASSF1 [35] and TET1 [36] for patient 4,010,017 (Table 5). Here, RASSF1 is linked to neoplasm.